News Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
85.18 ^USD	-2.37%		-6.95%	-7.65%

Mar. 22	Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	MT
Mar. 01	Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	Apr. 11	PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 04	PR
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	Mar. 22	MT
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 06	PR
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	Mar. 01	MT
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 26	AQ
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	Feb. 23	MT
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 23	CI
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	Feb. 22	CI
Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating	Feb. 15	MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	Feb. 15	MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	Feb. 15	MT
Transcript : Blueprint Medicines Corporation, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Blueprint Medicines: Q4 Earnings Snapshot	Feb. 15	AQ
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M	Feb. 15	MT
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024	Feb. 15	CI
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating	Feb. 13	MT
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 05	PR
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024	Feb. 01	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Summary

Filters